compstatin

Compstatin is a cyclic peptide consisting of 13 amino acid residues and is a potent inhibitor of complement system C3. Compstatin is species-specific and has inhibitory effects only on the complement system of primates. Studies have shown that it can bind to baboon C3 and is resistant to proteolytic cleavage in baboon blood. Its IC50 values for the classical pathway and alternative pathway are 63 μM and 12 μM, respectively.

Compstatin control peptide acetate is a negative control of Compstatin. Compstatin is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.

Compstatin TFA, a potent inhibitor of the complement system C3 characterized by species specificity, is a 13-residue cyclic peptide. It selectively binds to baboon C3 and demonstrates resistance to proteolytic cleavage in baboon blood (similar to humans), effectively inhibiting the activation of the primate complement system. Notably, Compstatin TFA exhibits IC 50 values of 63 μM and 12 μM for the classical and alternative complement pathways, respectively [1] [2] [3].

Compstatincontrol peptide TFA serves as a negative control for Compstatin, a potent inhibitor of the complement system's C3 (complement system C3).

POT-4 TFA (AL-78898A TFA), a derivative of Compstatin, efficiently inhibits the activation of complement factor C3 and is utilized in research related to age-related macular degeneration [1] [2].

Prafnosbart (DS-6016A) is a humanized IgG1-kappa monoclonal antibody that specifically targets Activin A Receptor Type 1 (ACVR1/ALK2). By binding to ACVR1, Prafnosbart blocks the binding of Activin A and the subsequent abnormal activation of downstream SMAD1/5/8 signaling pathways, thereby inhibiting the formation of heterotopic ossification (HO). Prafnosbart is primarily used to investigate bone metabolic disorders associated with ACVR1 mutations, such as Fibrodysplasia Ossificans Progressiva (FOP).